Publication | Open Access

Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode

Drug TargetSignal TransductionMedicineReceptor Tyrosine KinasePharmacologyStructure-based Drug DesignRational Drug DesignSystems BiologyMolecular DockingCell SignalingDrug DiscoveryDfg-out Binding Mode